|
Illumina Inc on Tuesday said it is collaborating with AstraZeneca PLC on drug target discovery, with a focus on artificial intelligence-based research on genes.
The San Diego, California and Cambridge, England based firms' research collaboration emphasises artificial intelligence based genome interpretation.
‘Illumina and AstraZeneca are uniquely positioned to improve the efficiency of pharma pipelines by leveraging industry-leading abilities to identify genetic variants that contribute to human disease,’ said Joydeep Goswami, chief strategy & corporate development officer and interim chief financial officer at Illumina.
‘By identifying genes that show evidence of human disease causality, the combined framework has the potential to prioritise drug candidates with increased likelihood of approval.’
Illumina Chief Technology Officer Alex Aravanis added: ‘The next generation of drug discovery lies at the intersection of human genetics and AI, making this a potentially pivotal research collaboration that combines Illumina's industry-leading ability to interpret genomes at scale with AstraZeneca's extensive capabilities in large-scale human genetics research.’
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
